Literature DB >> 14550683

S-adenosyl-L-methionine: effects on brain bioenergetic status and transverse relaxation time in healthy subjects.

Marisa M Silveri1, Aimee M Parow, Rosemond A Villafuerte, Karen E Damico, Jessica Goren, Andrew L Stoll, Bruce M Cohen, Perry F Renshaw.   

Abstract

BACKGROUND: S-adenosyl-L-methionine is an effective treatment for clinical depression, although the mechanism underlying this effect is unclear. Presently, in vivo phosphorus magnetic resonance spectroscopy (31P MRS) and brain transverse relaxometry were employed to test if S-adenosyl-L-methionine supplementation alters brain bioenergetics and/or transverse relaxation time (T2RT) in a nondepressed cohort. If these magnetic resonance techniques are sensitive to S-adenosyl-L-methionine induced alterations in neurochemical processes, these methods may be used in cases of clinical depression to elucidate the mechanism underlying the antidepressant effect of S-adenosyl-L-methionine.
METHODS: Twelve subjects self-administered 1600 mg of oral S-adenosyl-L-methionine daily. Phosphorus spectra and transverse relaxation time were acquired at baseline and after treatment using a 1.5 Tesla scanner.
RESULTS: Phosphocreatine levels were significantly higher after treatment, whereas beta nucleoside triphosphate levels, predominantly adenosine triphosphate in brain, were significantly lower after treatment. A surprising gender difference in T2RT emerged after supplementation, with women exhibiting significantly lower T2RT than men.
CONCLUSIONS: Alterations in phosphocreatine and beta nucleoside triphosphate are consistent with the report that S-adenosyl-L-methionine is involved in the production of creatine, which in turn is phosphorylated to phosphocreatine using adenosine triphosphate. These findings suggest that S-adenosyl-L-methionine alters parameters associated with cerebral bioenergetic status and that some effects of S-adenosyl-L-methionine (T2RT) occur in a gender-specific manner.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14550683     DOI: 10.1016/s0006-3223(03)00064-7

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  7 in total

1.  SAMe use in children and adolescents.

Authors:  James L Schaller; John Thomas; Anthony J Bazzan
Journal:  Eur Child Adolesc Psychiatry       Date:  2004-10       Impact factor: 4.785

2.  Epigenetics in mood disorders.

Authors:  Patrick O McGowan; Tadafumi Kato
Journal:  Environ Health Prev Med       Date:  2007-12-11       Impact factor: 3.674

3.  S-adenosylmethionine inhibits the growth of cancer cells by reversing the hypomethylation status of c-myc and H-ras in human gastric cancer and colon cancer.

Authors:  Jin Luo; Yan-Ni Li; Fei Wang; Wei-Ming Zhang; Xin Geng
Journal:  Int J Biol Sci       Date:  2010-12-06       Impact factor: 6.580

Review 4.  Diet and the epigenetic (re)programming of phenotypic differences in behavior.

Authors:  Patrick O McGowan; Michael J Meaney; Moshe Szyf
Journal:  Brain Res       Date:  2008-07-29       Impact factor: 3.252

5.  A randomized, double-blind placebo-controlled trial of oral creatine monohydrate augmentation for enhanced response to a selective serotonin reuptake inhibitor in women with major depressive disorder.

Authors:  In Kyoon Lyoo; Sujung Yoon; Tae-Suk Kim; Jaeuk Hwang; Jieun E Kim; Wangyoun Won; Sujin Bae; Perry F Renshaw
Journal:  Am J Psychiatry       Date:  2012-09       Impact factor: 18.112

6.  Creatine in Health and Disease.

Authors:  Richard B Kreider; Jeffery R Stout
Journal:  Nutrients       Date:  2021-01-29       Impact factor: 5.717

7.  S-Adenosylmethionine Treatment of Colorectal Cancer Cell Lines Alters DNA Methylation, DNA Repair and Tumor Progression-Related Gene Expression.

Authors:  Sára Zsigrai; Alexandra Kalmár; Zsófia B Nagy; Barbara K Barták; Gábor Valcz; Krisztina A Szigeti; Orsolya Galamb; Titanilla Dankó; Anna Sebestyén; Gábor Barna; Vanessza Szabó; Orsolya Pipek; Anna Medgyes-Horváth; István Csabai; Zsolt Tulassay; Péter Igaz; István Takács; Béla Molnár
Journal:  Cells       Date:  2020-08-09       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.